TABLE 1.

Distribution and divergence of IsdB in a collection of pathologically and taxonomically diverse S. aureus isolates

Strain	Source	Capsule type	MLST group^a	Antibiotic resistance group^b	% Identity to immunogen^c	Reactivity to anti-IsdB^d	MFI end titer^e
Strain	Source	Capsule type	MLST group^a	Antibiotic resistance group^b	% Identity to immunogen^c	Reactivity to anti-IsdB^d	RPMI	TSB	TSA
MCL 8567	Left forearm wound, United States	8	1	MSSA	100	+	21	8	0
MCL 8999	Arm wound, United States	8	1	MSSA	99	+	74	0	0
MCL 8752	Left foot, United States	5	5	MRSA	99	+	0	0	2
MCL 8072	Wound, United States	5	5	MRSA	99	+	22	23	0
MCL 8933	Right leg wound, United States	5	8	MRSA	100	+	38	0	0
ME9^f	Ireland, hospital acquired	5	8	MRSA		+	43	0	0
ME10^f	United Kingdom, hospital acquired, nares	5	9	MSSA	97	+	21	0	0
ME11^f^,^g	United Kingdom, blood	5	9	MSSA	97	+	87	9	19
ME13^f	The Netherlands, blood	8	12	MSSA	97	+	93	0	37
ME14^f	United Kingdom, nares	8	12	MSSA	97	+	1	0	3
MCL 8538^g	Left finger skin, United States	8	15	MSSA	98	+	78	19	13
MCL 8714	Pus left anaresle, United States	8	15	MSSA	98	+	22	0	0
ME24^f	United States, blood	5	22	MRSA		+	47	0	0
ME25^f	Germany, Barnin MRSA	5	22	MRSA	98	+	121	0	0
ME4^f	United States, blood	5	25	MRSA/VISA	98	+	87	0	0
ME27^f^,^g	Canada, blood	5	25	MRSA	97	+	58	19	1
ME31^f^,^g	Sweden, wound	8	30	MRSA	94	+	48	0	35
ME32^f	Germany, source not known	8	30	MRSA	94	+	4	15	6
MCL 8781	Left leg stump pus, United States	8	45	MRSA	95	+	96	0	0
Becker^g^,^h	United States prototype capsule strain	8	45	MSSA	95	+	192	0	0
ME54^f	The Netherlands, blood	5	97	MSSA	98	+	20	0	0
ME55^f	Canada, blood	5	97	MSSA	99	+	58	0	0
ME59^f	United Kingdom, nares, community disease	8	121	MSSA	96	+	93	0	0
ME60^f^,^g	United Kingdom, blood	8	121	MSSA	96	+	73	NDⁱ	0

↵a MLST group, multilocus sequence typing taxonomic group.
↵b MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus; VISA, S. aureus resistant to intermediate levels of vancomycin.
↵c Level of identity of the IsdB amino acid sequence to the amino acid sequence of IsdB from S. aureus COL, the source of the vaccine sequence used in the immunization experiments.
↵d S. aureus strains were grown in RPMI and screened for reactivity to IsdB antiserum from IsdB-immunized mice. +, binding to serum as detected by flow cytometry.
↵e MFI, mean fluorescene intensity when an anti-IsdB monoclonal antibody dilution of 1:500 was used.
↵f Clinical strain provided by Mark Enright, Imperial College, London, United Kingdom.
↵g Strain tested in the murine sepsis model using mice immunized with the IsdB vaccine.
↵h Strain provided by Chia Lee, University of Arkansas for Medical Sciences, Little Rock.
↵i ND, not determined.